Omega cuts 35% of workforce; Rhythm, CervoMed, Surrozen raise new funding

2024-04-01

蛋白降解靶向嵌合体

Plus: Trevena’s strategic review for its commercial drug, Algernon’s new focus and Antibe Therapeutics’ clinical hold.

Omega Therapeutics cuts 35% of workforce: The biotech had 93 employees at the end of 2023. Omega also prioritized its pipeline, but the move does not impact the pact it recently inked with Novo Nordisk. — Kyle LaHucik

Trevena seeks to offload commercial asset: The penny stock biotech says it has reduced commercial support to Olinvyk to preserve capital. It’s seeking strategic alternatives for the opioid drug. Instead, it will focus resources on its S1P receptor modulator, TRV045. — Amber Tong

Omega cuts 35% of workforce; Rhythm, CervoMed, Surrozen raise new funding

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构